{
  "drug_id": "D006",
  "drug_name": "Fenvora",
  "indication": "Oncology-C",
  "modality": "antibody-drug conjugate",
  "mechanism": "targeted receptor antagonist",
  "moa_short": "Blocks receptor-mediated signaling to reduce disease activity.",
  "formulation": "prefilled syringe",
  "route": "subcutaneous",
  "regimen": "300 mg Q2W",
  "trial_id": "AMGN-D006-201",
  "phase": "Phase 2",
  "arms": [
    {
      "name": "Fenvora 300 mg Q2W",
      "n": 186,
      "dose": "300 mg Q2W"
    },
    {
      "name": "Placebo",
      "n": 177,
      "dose": "matching regimen"
    }
  ],
  "population": "Adults with moderate-to-severe Oncology-C with inadequate response to standard therapy.",
  "key_inclusion": [
    "Confirmed diagnosis per protocol definition",
    "Baseline disease activity above threshold",
    "Stable background therapy for \u22654 weeks"
  ],
  "key_exclusion": [
    "Severe uncontrolled comorbidity (per protocol)",
    "Recent major surgery within 12 weeks",
    "Known hypersensitivity to components"
  ],
  "results": {
    "endpoint_primary": "Change from baseline in Symptom Score at Week 12",
    "endpoint_secondary": "Time to flare through Week 24",
    "primary_effect": "LS mean difference -1.35 (Drug \u2212 Placebo)",
    "primary_pvalue": 0.023102923866582865,
    "primary_ci": "[-1.75, -0.95]",
    "secondary_effect": "Met nominal significance in hierarchical testing",
    "discontinuation_rate_pct": 7.025049099900511
  },
  "safety": {
    "common_ae": [
      [
        "Fatigue",
        9.253097035082906
      ],
      [
        "Upper respiratory infection",
        6.434817473646747
      ],
      [
        "Arthralgia",
        5.623429329059172
      ],
      [
        "Diarrhea",
        6.017582016632869
      ],
      [
        "Rash",
        2.0
      ],
      [
        "Headache",
        2.0
      ]
    ],
    "serious_ae_rate_pct": 1.803347732519081,
    "discontinuation_ae_rate_pct": 4.945677155101382,
    "warnings": [
      "Monitor for hypersensitivity reactions.",
      "Assess for infection risk in susceptible patients.",
      "Consider hepatic monitoring if clinically indicated."
    ],
    "contraindications": [
      "Known hypersensitivity to active substance or excipients."
    ]
  },
  "monitoring": [
    "Baseline labs per protocol (CBC, CMP)",
    "Periodic assessment of liver enzymes",
    "Clinical monitoring for infections"
  ],
  "version": "v2.1",
  "doc_date": "2025-12-26"
}